干细胞治疗脓毒症的临床研究进展

doi:10.16352/j.issn.1001-6325.2025.09.1234

摘要/Abstract

摘要： 脓毒症(sepsis)是机体对感染反应失调引起的危及生命的急性器官功能障碍综合征。干细胞作为一种具有广泛应用前景的再生医学疗法,因其抗炎、抗氧化、抗凋亡、调节免疫和组织器官修复能力而备受关注。间充质干细胞(MSCs)可调控巨噬细胞极化、抑制过度炎性反应并促进组织修复,临床前研究显示MSCs可显著降低脓毒症的病死率,改善脓毒症相关急性肾损伤(AKI)、急性呼吸窘迫综合征(ARDS) 和脓毒症相关肌病。此外,围产期来源干细胞与修饰后的干细胞也显示出治疗脓毒症的潜力。当前干细胞治疗脓毒症挑战包括优化干细胞给药策略、标准化制备流程及开发生物标志物指导的个体化治疗。

关键词: 脓毒症, 干细胞, 急性呼吸窘迫综合征, 急性肾损伤, 脓毒症相关肌病

Abstract: Sepsis is a life-threatening acute organ dysfunction syndrome caused by a dys-regulated host response to infection. As a regenerative medicine therapy with broad clinical prospects, stem cells have attracted significant attention due to their multifaceted biological capabilities, including anti-inflammatory, antioxidant, and anti-apoptotic effects, as well as immunomodulatory properties and tissue/organ repair potential. Mesenchymal stem cells (MSCs) function through mechanisms such as modulating macrophage polarization and suppressing excessive inflammation responses, thereby promoting tissue regeneration. Pre-clinical studies demonstrate that MSCs significantly reduce sepsis mortality and decrease sepsis-associated complications including acute kidney injury (AKI), acute respiratory distress syndrome (ARDS) and sepsis associated myopathy. Furthermore, perinatal-derived stem cells and genetically modified stem cells have shown therapeutic promise in sepsis management. Current challenges in stem cell-based sepsis therapy cover optimizing delivery strategies, standardizing cell preparation protocols and developing biomarker-guided personalized therapeutic regimens.

Key words: sepsis, stem-cell, acute respiratory distress syndrome, acute kidney injury, sepsis associated myopathy

中图分类号:

R459.9

牛昕妤, 孙志明, 谢旻, 李双玲. 干细胞治疗脓毒症的临床研究进展[J]. 基础医学与临床, 2025, 45(9): 1234-1238.

NIU Xinyu, SUN Zhiming, XIE Min, LI Shuangling. Advances in clinical research on stem cell therapy for sepsis[J]. Basic & Clinical Medicine, 2025, 45(9): 1234-1238.

参考文献

[1] Meyer NJ, Prescott HC. Sepsis and septic shock[J]. N Engl J Med, 2024, 391: 2133-2146.doi:10.1056/nejmra2403213.
[2] Selim SA, El-Baset SAA, Kattaia AAA, et al. Bone marrow-derived mesenchymal stem cells ameliorate liver injury in a rat model of sepsis by activating Nrf2 signaling[J]. Histochem Cell Biol, 2019, 151: 249-262.doi:10.1007/s00418-018-1731-4.
[3] Ding JY, Chen MJ, Wu LF, et al. Mesenchymal stem cell-derived extracellular vesicles in skin wound healing: roles, opportunities and challenges[J]. Mil Med Res, 2023, 10: 36.doi:10.1186/s40779-023-00472-w.
[4] Aghayan AH, Mirazimi Y, Fateh K, et al. Therapeutic effects of mesenchymal stem cell-derived extracellular vesicles in sepsis: a systematic review and Meta-analysis of preclinical studies[J]. Stem Cell Rev Rep, 2024, 20: 1480-1500.doi:10.1007/s12015-024-10741-3.
[5] Khosrojerdi A, Soudi S, Hosseini AZ, et al. Immunomodulatory and therapeutic effects of mesenchymal stem cells on organ dysfunction in sepsis[J]. Shock, 2021, 55: 423-440.doi:10.1097/SHK.0000000000001644.
[6] Sun XY, Ding XF, Liang HY, et al. Efficacy of mesenchymal stem cell therapy for sepsis: a Meta-analysis of preclinical studies[J]. Stem Cell Res Ther, 2020, 11: 214.doi:10.1186/s13287-020-01730-7.
[7] Ou Q, Tan L, Shao Y, et al. Electrostatic charge-mediated apoptotic vesicle biodistribution attenuates sepsis by switching neutrophil NETosis to apoptosis[J]. Small, 2022, 18: e2200306.doi:10.1002/smll.202200306.
[8] Dos Santos CC, Amatullah H, Vaswani CM, et al. Mesenchymal stromal (stem) cell therapy modulates miR-193b-5p expression to attenuate sepsis-induced acute lung injury[J]. Eur Respir J, 2022, 59.doi:10.1183/13993003.04216-2020.
[9] Ma Y, She X, Liu Y, et al. MSC-derived exosomal miR-140-3p improves cognitive dysfunction in sepsis-associated encephalopathy by HMGB1 and S-lactoylglutathione metabolism[J]. Commun Biol, 2024, 7: 562.doi:10.1038/s42003-024-06236-z.
[10] Aliniay-Sharafshadehi S, Yousefi MH, Ghodratie M, et al. Exploring the therapeutic potential of different sources of mesenchymal stem cells: a novel approach to combat burn wound infections[J]. Front Microbiol, 2024, 15: 1495011.doi:10.3389/fmicb.2024.1495011.
[11] Lehmann TP, Golik M, Olejnik J, et al. Potential applications of using tissue-specific EVs in targeted therapy and vaccinology[J]. Biomed Pharmacother, 2023, 166: 115308.doi:10.1016/j.biopha.2023.115308.
[12] He X, Ai S, Guo W, et al. Umbilical cord-derived mesenchymal stem (stromal) cells for treatment of severe sepsis: aphase 1 clinical trial[J]. Transl Res, 2018, 199: 52-61.doi:10.1016/j.trsl.2018.04.006.
[13] Galstian GM, Parovichnikova EN, Makarova PM, et al. The results of the Russian clinical trial of mesenchymal stromal cells (MSCs) in severe neutropenic patients (pts) with septic shock (SS) (RUMCESS trial)[J]. Blood, 2015, 126: 2220.doi:10.1182/blood.V126.23.2220.2220.
[14] Meng SS, Guo FM, Zhang XW, et al. mTOR/STAT-3 pathway mediates mesenchymal stem cell-secreted hepatocyte growth factor protective effects against lipopolysaccharide-induced vascular endothelial barrier dysfunction and apoptosis[J]. J Cell Biochem, 2019, 120: 3637-3650.doi:10.1002/jcb.27642.
[15] Hashemian SMR, Aliannejad R, Zarrabi M, et al. Mesenchymal stem cells derived from perinatal tissues for treatment of critically ill COVID-19-induced ARDS patients: a case series[J]. Stem Cell Res Ther, 2021, 12: 91.doi:10.1186/s13287-021-02165-4.
[16] Matthay MA, Calfee CS, Zhuo H, et al. Treatment with allogeneic mesenchymal stromal cells for moderate to severe acute respiratory distress syndrome (START study): a randomised phase 2a safety trial[J]. Lancet Respir Med, 2019, 7: 154-162.doi:10.1016/S2213-260030418-1.
[17] Singer NG, Caplan AI. Mesenchymal stem cells: mechanisms of inflammation[J]. Annu Rev Pathol: Pathol Mech Dis, 2011, 6: 457-478.
[18] Ye Q, Qiu X, Wang J, et al. MSCs-derived apoptotic extracellular vesicles promote muscle regeneration by inducing Pannexin 1 channel-dependent creatine release by myoblasts[J] Int J Oral Sci, 2023, 15: 7.doi:10.1038/s41368-022-00205-0.
[19] Zhang Q, Lai D. Application of human amniotic epithelial cells in regenerative medicine: a systematic review[J]. Stem Cell Res Ther, 2020, 11: 439.doi:10.1186/s13287-020-01951-w.
[20] Chi D, Chen Y, Xiang C, et al. Human amnion epithelial cells and their derived exosomes alleviate sepsis-associated acute kidney injury via mitigating endothelial dysfunction[J]. Front Med, 2022, 9: 829606.doi:10.3389/fmed.2022.829606.
[21] Sato Y, Ochiai D, Abe Y, et al. Prophylactic therapy with human amniotic fluid stem cells improved survival in a rat model of lipopolysaccharide-induced neonatal sepsis through immunomodulation via aggregates with peritoneal macrophages[J]. Stem Cell Res Ther, 2020, 11: 300.doi:10.1186/s13287-020-01809-1.
[22] Abe Y, Ochiai D, Sato Y, et al. Prophylactic therapy with human amniotic fluid stem cells improves long-term cognitive impairment in rat neonatal sepsis survivors[J]. Int J Mol Sci, 2020, 21.doi:10.3390/ijms21249590.
[23] Li Z, Song Y, Yuan P, et al. Antibacterial fusion protein BPI21/LL-37 modification enhances the therapeutic efficacy of hUC-MSCs in sepsis[J]. Mol Ther, 2020, 28: 1806-1817.doi:10.1016/j.ymthe.2020.05.014.
[24] Lu L, Quan L, Li J, et al. Bioengineered stem cell membrane functionalized nanoparticles combine anti-inflammatory and antimicrobial properties for sepsis treatment[J]. J Nanobiotechnol, 2023, 21: 170.doi:10.1186/s12951-023-01913-3.
[25] Sinha P, Kerchberger VE, Willmore A, et al. Identifying molecular phenotypes in sepsis: an analysis of two prospective observational cohorts and secondary analysis of two randomised controlled trials[J]. Lancet Respir Med, 2023, 11: 965-974. doi:10.1016/S2213-260000237-0.